Eli Lilly & Co. Ends Partnership with UCSD for Asymptomatic Alzheimer’s Disease Study With Solanezumab

Eli Lilly & Co. Ends Partnership with UCSD for Asymptomatic Alzheimer’s Disease Study With Solanezumab
Soon-to-be former partners in a promising Alzheimer’s research program, Eli Lilly and Co. and the University of California San Diego (UCSD) have moved a step closer to ending the contract that covers the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) study, a groundbreaking clinical trial that aims to test solanezumab. This Phase 3 monoclonal antibody binds to

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *